Engineered high-density lipoprotein particles that chaperone bioactive lipid mediators to combat endothelial dysfunction and thromboinflammation
Steven Swendeman(Boston Children's Hospital), Timothy Hla(American Red Cross), Robert Flaumenhaft(Beth Israel Deaconess Medical Center), Garret A. FitzGerald(Translational Therapeutics (United States)), Samir M. Parikh(Beth Israel Deaconess Medical Center), Takahiro Seno(Boston Children's Hospital), Andrew Kuo(Boston Children's Hospital), Alan Culbertson(Harvard University), Andréane Cartier(Boston Children's Hospital), Michel V. Levesque(Boston Children's Hospital), Asuka Inoue(Tohoku University), Daniel W. Lin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Maofu Liao(Harvard University), Sylvain Galvani(Boston Children's Hospital), Alec A. Schmaier(Beth Israel Deaconess Medical Center), Shihui Guo(Beth Israel Deaconess Medical Center)
Cited by 1
Related Papers
Prostaglandins and Inflammation
|Arteriosclerosis Thrombosis and Vascular Biology|2011|3.7k
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
|Pharmacological Reviews|2004|1.7k
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
|New England Journal of Medicine|2001|1.4k